NanoRepro AG Logo

NanoRepro AG

Develops and distributes rapid diagnostic self-tests for early disease detection.

NN6 | F

Overview

Corporate Details

ISIN(s):
DE0006577109
LEI:
3912008FCA63AGIMEV74
Country:
Germany
Address:
UNTERGASSE 8, 35037 MARBURG

Description

NanoRepro AG is an innovative leader in the development, manufacturing, and distribution of CE-marked rapid diagnostic tests (self-tests) and food supplements. The company serves both home and professional markets, domestically and internationally. Its product portfolio is designed to provide rapid and accurate results for early disease detection and preventive healthcare. Key product categories include family planning, disease detection, food intolerances, allergies, and infectious diseases. The company's stated goal is to provide accuracy in self-diagnostics for rapid disease detection.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-10 08:35
NanoRepro AG: Aufsichtsratsmitglied kundigt Amtsniederlegung an
German 6.8 KB
2025-12-09 18:50
NanoRepro AG: Aufsichtsratin kundigt Amtsniederlegung an
German 6.8 KB
2025-12-05 22:30
NanoRepro AG: Einberufungsverlangen fur eine auerordentliche Hauptversammlung z…
German 10.6 KB
2025-10-31 12:00
NanoRepro AG: Halbjahreszahlen 2025 - NanoRepro setzt Wachstumskurs fort
German 16.4 KB
2025-09-05 00:00
Datum:05.09.2025
German 442.2 KB
2025-08-20 14:30
NanoRepro AG: Aktuelle GBC-Studie mit Kursziel 4,50 Euro
German 13.2 KB
2025-08-05 14:00
NanoRepro AG: Lisa Jungst, buy
German 6.0 KB
2025-07-21 00:00
Berichtigung der Veröffentlichung vom 14.03.2025
German 15.0 KB
2025-07-18 15:00
NanoRepro AG: Endgultige Jahreszahlen 2024 - NanoRepro bleibt auf Wachstumskurs
German 14.4 KB
2025-05-26 14:01
NanoRepro AG: Dr. Olaf Stiller, buy
German 6.0 KB
2025-05-19 12:01
NanoRepro AG: Dr. Olaf Stiller, buy
German 6.0 KB
2025-05-08 15:01
NanoRepro AG: Dr. Olaf Stiller, buy
German 5.9 KB
2025-04-29 14:00
NanoRepro AG: NanoRepro AG investiert in Kaltplasma-Technologie und baut ihre M…
German 11.4 KB
2025-04-16 14:00
NanoRepro AG: NanoRepro erhalt EU-Qualitatsmanagementbescheinigung nach Verordn…
German 8.9 KB
2025-03-27 15:46
NanoRepro AG: Dr. Olaf Stiller, buy
German 5.9 KB

Automate Your Workflow. Get a real-time feed of all NanoRepro AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NanoRepro AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NanoRepro AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-02-25 Stiller, Dr. Olaf Supervisory board Buy None 14,506.24 EUR
2025-02-17 Stiller, Dr. Olaf Supervisory board Buy None 18,750.00 EUR
2024-10-29 Stiller, Dr. Olaf Supervisory board Buy None 17,300.00 EUR
2024-10-22 Stiller, Dr. Olaf Supervisory board Buy None 8,949.96 EUR
2024-10-22 Stiller, Dr. Olaf Supervisory board Buy None 8,500.00 EUR
2024-10-21 Stiller, Dr. Olaf Supervisory board Buy None 8,750.00 EUR
2024-10-21 Stiller, Johanna Close relation Buy None 3,759.00 EUR
2024-08-30 ASS GmbH Close relation Buy None 30,644.30 EUR
2024-07-25 Stiller, Dr. Olaf Supervisory board Buy None 3,279.18 EUR
2024-07-24 Jüngst, Lisa Board Buy None 21,762.00 EUR

Peer Companies

Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea
068270
Celltrion Pharm Inc. Logo
South Korea
068760
Develops bone grafts, artificial joints, and enzymes for the biopharmaceutical sector.
South Korea
049180
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN
Celularity Inc Logo
Develops off-the-shelf cell therapies from placentas for cancer and aging-related diseases.
United States of America
CELU
Centessa Pharmaceuticals plc Logo
Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.
United States of America
CNTA
Century Therapeutics, Inc. Logo
Developing iPSC-derived, off-the-shelf cell therapies for cancer & autoimmune diseases.
United States of America
IPSC
Cereno Scientific AB Logo
Develops epigenetic therapies for rare cardiovascular and pulmonary diseases.
Sweden
CRNO
CERO THERAPEUTICS HOLDINGS, INC. Logo
Develops engineered T-cell immunotherapies for cancer using its proprietary CER platform.
United States of America
CERO
CERUS CORP Logo
Develops pathogen reduction technology to safeguard the global blood supply for healthcare providers.
United States of America
CERS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.